FDA Approves Dupilumab for Atopic Dermatitis in Children 6 Months to 5 Years
Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis.
Regeneron Buys Rights to Pembrolizumab from Sanofi
Regeneron Pharmaceuticals Inc came to an agreement to buy the drug from Sanofi for up to $1.1 billion.
Bimekizumab Fails to Pass FDA Pre-Approval Inspection
UCB announced the FDA issued a CRL that stated that the FDA cannot approve the BLA in its current form.
The Drug Pipeline for Vitiligo
Ruxolitinib cream 1.5% may soon be the first FDA-approved treatment for repigmentation of vitiligo. Experts share what dermatologists need to know regarding efficacy, safety, and cost of this topical drug.
Survey: Misunderstanding Sun Protection is a Common Problem
An American Academy of Dermatology survey found that more Americans say sun protection is more important than 5 years ago, but don’t understand how to protect themselves.
FDA Approves Epsolay for Inflammatory Lesions of Rosacea
Sol-Gel Technologies and Galderma announced the FDA approval of the 5% benzoyl peroxide, cream for the treatment of inflammatory lesions of rosacea.
Evaluating Real-World Dupilumab Data
A supplemental biologics license application was recently submitted.
Adverse Events of ALA-PDT Treatment for Acne Evaluated
A recent study investigated the potential adverse events around using 5-aminolaevulinic acid photodynamic therapy (ALA-PDT) for acne treatment.
Examining Skin Cancer Prevalence in Incarcerated Populations
A recent study investigated how the limited access to specialty care in these populations may affect the detection and diagnosis of skin cancer.
AAD Guidelines Evaluate Links Between Atopic Dermatitis, Comorbidities
The American Academy of Dermatology’s newest guideline focuses on awareness of other health conditions associated with atopic dermatitis in adult patients.
Small Increased COVID-19 Risk with Atopic Dermatitis
A retrospective cohort study in a research letter published in the Journal of the American Academy of Dermatology examined the risk between atopic dermatitis and COVID-19 risk.
Study: The Link Between Diabetes, Obesity and Psoriasis Treatment
A study published in the Journal of the American Academy of Dermatology did a prospective analysis on psoriasis biologic treatment response related to comorbid obesity and a history of diabetes.
Patients Willing to Use Medical Cannabis for Dermatology Conditions
A national survey found that patients are willing to try medical cannabis products as potential treatments of their condition. Additionally, some already use over-the-counter cannabis products.
Acne Treatment Meets End Points in Study
IDP-126, an acne vulgaris treatment for patients ages 9 and older, met all of its endpoints in a 12-week phase 3 study.